On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…
HOME > REGULATORY
REGULATORY
- MHLW Aims for Passage of Bill to Amend PAL during Extraordinary Diet Session This Autumn
July 1, 2013
- Study Group Approves Guidelines for Use of Medical Information Database During Trial Period
June 28, 2013
- Cost-Effective Assessment for Medical Devices Presented at CSIMC Subcommittee; Reps Say They Want Examples for Pharmaceuticals Too
June 27, 2013
- MHLW Maps Out New Vision for Pharma Industry; Research-Based Makers Will See “Survival of the Fittest,” It Says
June 27, 2013
- HSC’s Vaccination Policy Committee Approves Switch to 13-Valent Pediatric Pneumococcal Vaccine
June 26, 2013
- Patients Would Like to See Their Drug Costs Reduced by Half; Further Reductions in Generic Drug Prices to Become a Topic: Pharmaceutical Management Director Chikazawa
June 25, 2013
- LDP Election Platform Targets 16 Trillion Yen Healthcare Market in 2020
June 24, 2013
- 47 Products Including an AG of Allegra, but not That of Livalo, Added to NHI Price List in Latest Generic Listing
June 24, 2013
- First Generics for 5 Products Including Prograf, TS-1 Added to NHI Drug Price List
June 24, 2013
- FPMAJ May Find it Difficult to Compile Unified Statement of Views on TPP Talks Due to Disagreement among Original and Generic Drug Makers
June 24, 2013
- MHLW to Resume Inviting Requests for Development of Unapproved Drugs, Indications; No Deadline Set This Time
June 20, 2013
- MHLW to Quickly Compile Studies on Reported HPV Vaccine Adverse Events, Give Clear Explanation to Public: Minister Tamura
June 20, 2013
- Top Priorities for Next Midterm Plan to Include Greater Sophistication in Review and Consultation: PMDA
June 20, 2013
- MHLW to Temporarily Withdraw Recommendation of Preventive Cervical Cancer Vaccinations
June 18, 2013
- PMDA Building “Database on Unapproved Drugs” to Accelerate Elimination of Drug Lag
June 18, 2013
- Cabinet Approves PM Abe’s Growth Strategy, Regulatory Reform Plan
June 17, 2013
- Council to Discuss Problem of Prolonged Delivery Price Negotiations at Meeting on June 27
June 17, 2013
- Pharmaceutical Affairs Council Approves Revised Draft Plan to Reduce Manufacturing Costs of Blood Products
June 17, 2013
- CSIMC’s Expert Subcommittee on NHI Drug Pricing Affairs to Hold Hearings for Drug Pricing Organization at Next Meeting in July
June 14, 2013
- CSIMC Approves Plans for FY2013 Market Price Survey of Similar Size as 2 Years Ago
June 14, 2013
ページ
Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…